ARTLHIGH SIGNALFINANCIAL10-K

ARTL's stockholders' equity collapsed from $2.9M to -$1.3M while cash reserves plummeted 91% to just $600K, indicating severe financial distress.

The company has moved from positive to negative stockholders' equity, signaling potential insolvency concerns and raising questions about its ability to continue operations. The dramatic cash burn combined with deteriorating net losses suggests ARTL may face significant financing challenges or dilutive equity raises in the near term.

Comparing 2026-02-24 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

ARTL's financial position deteriorated catastrophically with cash & equivalents falling 91% to only $600K while current liabilities more than doubled to $4.0M, creating a severe liquidity crisis. The balance sheet shifted from positive $2.9M stockholders' equity to negative $1.3M, accompanied by worsening net losses increasing 31% to -$12.9M. This combination of rapid cash depletion, mounting liabilities, and accelerating losses signals acute financial distress that threatens the company's operational continuity.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-144.5%
$2.9M-$1.3M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Liabilities
Balance Sheet
+128.2%
$1.8M$4.0M

Current liabilities surged 128.2% — significant near-term obligations; verify ability to meet short-term debt.

Total Liabilities
Balance Sheet
+121.2%
$1.8M$4.1M

Liabilities grew 121.2% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
-91.3%
$6.9M$600K

Cash declined 91.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-72.8%
$2.6M$695K

Current assets declined 72.8% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-40.4%
$4.7M$2.8M

Total assets contracted 40.4% — asset sales, write-downs, or balance sheet optimization underway.

Net Income
P&L
-31.1%
-$9.8M-$12.9M

Net income declined 31.1% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-12.8%
-$10.1M-$11.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-03-03
ADDED
The registrant had 2,124,772 shares of Common Stock issued and outstanding as of February 20, 2026.
Some of the statements in the sections captioned Risk Factors , Management s Discussion and Analysis of Financial Condition and Results of Operations , Business , and elsewhere contain forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.
In this Annual Report on Form 10-K, unless otherwise specified, all dollar amounts are expressed in United States dollars ( USD ) and all references to common shares refer to shares of our Common Stock.
This synthetic small molecule program is a G protein-coupled receptor ( GPCR ) designated ART27.13 and was initially developed by AstraZeneca plc.
+7 more — sign up free →
REMOVED
The Registrant had 3,281,032 shares of common stock issued and outstanding as of February 27, 2025.
Some of the statements in the sections captioned Risk Factors, Management s Discussion and Analysis of Financial Condition and Results of Operations, Business, and elsewhere contain forward-looking statements.
Unless otherwise noted, all amounts are expressed in United States dollars ( USD ) and we , us , our and the Company refer to Artelo Biosciences, Inc., including its subsidiaries unless otherwise indicated.
In this Annual Report on Form 10-K, unless otherwise specified, all dollar amounts are expressed in USD and all references to Common Shares refer to shares of our common stock.
This synthetic small molecule program is a G protein-coupled receptor ( GPCR ) designated ART27.13.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →